MA38194A1 - Anticorps anti-ceacam5 et leurs utilisations - Google Patents

Anticorps anti-ceacam5 et leurs utilisations

Info

Publication number
MA38194A1
MA38194A1 MA38194A MA38194A MA38194A1 MA 38194 A1 MA38194 A1 MA 38194A1 MA 38194 A MA38194 A MA 38194A MA 38194 A MA38194 A MA 38194A MA 38194 A1 MA38194 A1 MA 38194A1
Authority
MA
Morocco
Prior art keywords
antibodies
immunoconjugates
ceacam5 antibodies
conjugated
vectors
Prior art date
Application number
MA38194A
Other languages
English (en)
Other versions
MA38194B1 (fr
Inventor
Pierre-Francois Berne
Francis Blanche
Hervé Bouchard
Béatrice Cameron
Tarik Dabdoubi
Stéphanie Decary
Paul Ferrari
Alexey Rak
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA38194A1 publication Critical patent/MA38194A1/fr
Publication of MA38194B1 publication Critical patent/MA38194B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des anticorps qui se lient à des protéines ceacam5 humaines et de macaca fascicularis ainsi que des acides nucléiques isolés, des vecteurs et des cellules hôtes comprenant une séquence codant pour les anticorps. L'invention concerne également des immunoconjugués comprenant les anticorps conjugués ou liés à un agent d'inhibition de croissance, et des compositions pharmaceutiques comprenant des anticorps ou des immunoconjugués. Les anticorps ou les immunoconjugués de l'invention sont utilisés pour traiter le cancer ou à des fins de diagnostic.
MA38194A 2012-11-20 2013-11-20 Anticorps anti-ceacam5 et leurs utilisations MA38194B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306444 2012-11-20
PCT/EP2013/074291 WO2014079886A1 (fr) 2012-11-20 2013-11-20 Anticorps anti-ceacam5 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA38194A1 true MA38194A1 (fr) 2018-02-28
MA38194B1 MA38194B1 (fr) 2018-12-31

Family

ID=47257727

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38194A MA38194B1 (fr) 2012-11-20 2013-11-20 Anticorps anti-ceacam5 et leurs utilisations

Country Status (38)

Country Link
US (4) US9617345B2 (fr)
EP (3) EP2922875B1 (fr)
JP (1) JP6324399B2 (fr)
KR (4) KR102194748B1 (fr)
CN (2) CN104918958B (fr)
AR (1) AR093557A1 (fr)
AU (2) AU2013349733C1 (fr)
BR (1) BR112015010993B1 (fr)
CA (2) CA2889962C (fr)
CL (1) CL2015001321A1 (fr)
CR (1) CR20150258A (fr)
CY (1) CY1119219T1 (fr)
DK (2) DK2922875T3 (fr)
DO (1) DOP2015000110A (fr)
EA (1) EA039377B1 (fr)
EC (1) ECSP15025845A (fr)
ES (2) ES2778823T3 (fr)
HR (2) HRP20170743T1 (fr)
HU (1) HUE033369T2 (fr)
IL (1) IL238559B (fr)
LT (2) LT2922875T (fr)
MA (1) MA38194B1 (fr)
MX (1) MX358321B (fr)
MY (1) MY171100A (fr)
NZ (1) NZ708528A (fr)
PE (1) PE20151180A1 (fr)
PH (1) PH12015501092B1 (fr)
PL (2) PL2922875T3 (fr)
PT (2) PT3199552T (fr)
RS (2) RS60043B1 (fr)
SG (1) SG11201503285TA (fr)
SI (2) SI2922875T1 (fr)
TN (1) TN2015000177A1 (fr)
TW (2) TWI664192B (fr)
UA (1) UA120247C2 (fr)
UY (1) UY35147A (fr)
WO (1) WO2014079886A1 (fr)
ZA (1) ZA201502959B (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
PT3199552T (pt) 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
US9753036B2 (en) * 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
MA40539A (fr) * 2014-09-02 2016-03-10 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicaments
JP7044700B2 (ja) 2015-10-02 2022-03-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子
BR112018011029A2 (pt) 2016-01-08 2018-11-21 Hoffmann La Roche métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
KR102580319B1 (ko) * 2016-10-10 2023-09-19 에이전시 포 사이언스, 테크놀로지 앤드 리서치 항 ceacam6 항체 및 사용 방법
WO2018092885A1 (fr) 2016-11-18 2018-05-24 アステラス製薬株式会社 NOUVEAU FRAGMENT Fab D'ANTICORPS ANTI-MUC1 HUMAIN
CN111533805B (zh) * 2016-12-04 2022-02-08 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的高亲和力纳米抗体及其应用
CN108341876B (zh) * 2017-01-22 2021-06-04 中国人民解放军第四军医大学 抗人ceacam5单克隆抗体及其制备方法和应用
CN106946989B (zh) * 2017-03-02 2020-02-18 深圳市国创纳米抗体技术有限公司 抗cea抗原vhh结构域及含有其的双特异性抗体
TWI795415B (zh) * 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
RU2020100072A (ru) * 2017-07-11 2021-08-11 Пфайзер Инк. Иммуногенные композиции, содержащие cea, muc1 и tert
EP3502140A1 (fr) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Thérapie de combinaison d'agonistes d'icos ciblés contre la tumeur avec des molécules bispécifiques à cellules t
AU2019235634A1 (en) 2018-03-13 2020-10-22 Zymeworks Bc Inc. Anti-HER2 biparatopic antibody-drug conjugates and methods of use
WO2019195770A1 (fr) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions et procédés comprenant des anticorps anti-nrp2
EP3781592A4 (fr) * 2018-04-20 2023-01-11 The Regents of the University of California Traitement du cancer de la prostate au moyen de récepteurs antigéniques chimériques
US12202908B2 (en) 2018-05-17 2025-01-21 Astellas Pharma Inc. Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
CN112566938B (zh) 2018-06-03 2025-04-01 拉姆卡普生物测试有限公司 针对ceacam5和cd47的双特异性抗体
TWI920652B (zh) 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
CN110684107B (zh) * 2018-07-06 2021-03-23 中国人民解放军第四军医大学 抗MG7-Ag的单克隆抗体(MGd1)及其用途
CN110684108B (zh) * 2018-07-06 2021-06-04 中国人民解放军第四军医大学 抗MG7-Ag的单克隆抗体(CEA37)及其用途
CA3109139A1 (fr) 2018-08-30 2020-03-05 HCW Biologics, Inc. Methodes de traitement de troubles lies au vieillissement
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
WO2020047333A1 (fr) 2018-08-30 2020-03-05 HCW Biologics, Inc. Polypeptides chimériques à chaîne unique et leurs utilisations
MX2021004146A (es) 2018-10-10 2021-06-08 Astellas Pharma Inc Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado.
CN111487411B (zh) * 2019-01-29 2023-05-09 瑞博奥(广州)生物科技股份有限公司 Ceacam1多肽的新应用
EP3693023A1 (fr) 2019-02-11 2020-08-12 Sanofi Utilisation d'immuno-conjugués anti-ceacam5 pour le traitement du cancer du poumon
KR20210124260A (ko) 2019-02-07 2021-10-14 사노피 폐암을 치료하기 위한 항-ceacam5 면역접합체의 용도
WO2020216847A1 (fr) * 2019-04-23 2020-10-29 Sanofi Formulations d'anticorps stables et à faible viscosité et leurs utilisations
TWI844684B (zh) * 2019-06-04 2024-06-11 大陸商普米斯生物技術（珠海）有限公司 一種抗ceacam5的單殖株抗體及其製備方法和用途
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
JP2022537158A (ja) 2019-06-13 2022-08-24 ボルト バイオセラピューティクス、インコーポレーテッド アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用
AU2020294797B2 (en) 2019-06-21 2025-12-18 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
EP3990492A1 (fr) 2019-06-27 2022-05-04 F. Hoffmann-La Roche AG Nouveaux anticorps anti-icos et molécules de liaison à un antigène ciblant les tumeurs les comprenant
US20220313835A1 (en) 2019-09-03 2022-10-06 Bolt Biotherapeutics, Inc. Aminoquinoline compounds, immunoconjugates, and uses thereof
AU2020350205A1 (en) 2019-09-18 2022-05-12 Lamkap Bio Alpha AG Bispecific antibodies against CEACAM5 and CD3
EP4038053A1 (fr) 2019-09-30 2022-08-10 Bolt Biotherapeutics, Inc. Immunoconjugués d'aminobenzazépine liés à des amides et leurs utilisations
AU2020358854B2 (en) 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
EP4048315B1 (fr) 2019-10-25 2025-03-12 Bolt Biotherapeutics, Inc. Immunoconjugués de thiénoazépine et leurs utilisations
EP3831849A1 (fr) 2019-12-02 2021-06-09 LamKap Bio beta AG Anticorps bispécifiques contre ceacam5 et cd47
WO2021163299A1 (fr) 2020-02-11 2021-08-19 HCW Biologics, Inc. Résine de chromatographie et utilisations associées
CN116670163A (zh) 2020-02-11 2023-08-29 Hcw生物科技公司 治疗年龄相关疾病和炎性疾病的方法
CA3169243A1 (fr) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methodes d'activation de lymphocytes t regulateurs
BR112022020477A2 (pt) 2020-04-24 2022-11-29 Sanofi Sa Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e cetuximabe
EP4138925A1 (fr) * 2020-04-24 2023-03-01 Sanofi Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5, de la trifluridine et du tipiracil
CN115427082A (zh) * 2020-04-24 2022-12-02 赛诺菲 含有抗ceacam5抗体缀合物和folfox的抗肿瘤组合
CA3181000A1 (fr) * 2020-04-24 2021-10-28 Sanofi Combinaisons antitumorales contenant des conjugues d'anticorps anti-ceacam5 et du folfiri
AU2021262794B2 (en) 2020-04-29 2026-06-18 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
CA3176626A1 (fr) 2020-05-08 2021-11-11 David Dornan Substrat pour elastase, immunoconjugues de liaison peptidique et leurs utilisations
WO2021247003A1 (fr) 2020-06-01 2021-12-09 HCW Biologics, Inc. Méthodes de traitement de troubles liés au vieillissement
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
IL298608A (en) 2020-06-01 2023-01-01 Hcw Biologics Inc Methods for treating disorders related to aging
CN111690061B (zh) * 2020-06-28 2022-08-23 中国人民解放军东部战区疾病预防控制中心 人源化抗鼠疫耶尔森菌抗原f1的抗体及应用
CN113105549B (zh) * 2020-08-04 2022-04-01 中山大学附属第五医院 抗ceacam5纳米抗体
MX2023001679A (es) 2020-08-13 2023-02-22 Bolt Biotherapeutics Inc Inmunoconjugados de pirazolazepina y usos de estos.
WO2022040454A1 (fr) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions et méthodes de traitement de cancers positifs à la mésothéline
US11433100B2 (en) 2020-08-20 2022-09-06 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
EP4097486A4 (fr) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. Compositions et méthodes de traitement de cancers positifs à ceacam
US20250122282A2 (en) * 2020-09-04 2025-04-17 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
JP7849358B2 (ja) 2020-11-10 2026-04-21 サノフイ Ｃｅａｃａｍ５抗体－薬物コンジュゲート製剤
WO2022116079A1 (fr) * 2020-12-03 2022-06-09 上海吉倍生物技术有限公司 Anticorps anti-ceacam5 humanisé et son procédé de préparation et son utilisation
WO2022125891A2 (fr) 2020-12-11 2022-06-16 Bolt Biotherapeutics, Inc. Immunoconjugués anti-cea et leurs utilisations
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
JP2024505333A (ja) 2020-12-21 2024-02-06 フリーノム ホールディングス，インク． 結腸細胞増殖障害の早期検出のためのマーカー
CN112521509B (zh) * 2020-12-23 2022-07-08 姚雪英 一种抗ceacam5人源化抗体、其缀合物及其用途
JP2024513313A (ja) * 2021-03-08 2024-03-25 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション ＣＤ６６ｅポリペプチドに結合する分子
CN117940168A (zh) 2021-03-26 2024-04-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
CN117769439A (zh) 2021-03-26 2024-03-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂卓免疫缀合物及其用途
EP4341299A4 (fr) * 2021-05-21 2026-01-14 Beone Medicines I Gmbh Anticorps anti-cea et méthodes d'utilisation
CN117396182A (zh) * 2021-05-21 2024-01-12 百济神州有限公司 抗cea和抗cd137多特异性抗体及其使用方法
JP2024536382A (ja) 2021-10-07 2024-10-04 サノフイ イミダゾ［４，５－ｃ］キノリン－４－アミン化合物及びそのコンジュゲート、それらの調製並びにそれらの治療用途
JP2024540374A (ja) * 2021-11-05 2024-10-31 アメリカン ダイアグノスティックス アンド セラピー， エルエルシー （エーディーエックスアールエックス） がん胎児性抗原に対するモノクローナル抗体、及びそれらの使用
AU2022382383A1 (en) 2021-11-05 2024-06-20 Eli Lilly And Company Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
MX2024006766A (es) 2021-12-02 2024-07-29 Sanofi Sa Prueba de cea para la selección de pacientes en tratamiento del cáncer.
JP2024545427A (ja) 2021-12-02 2024-12-06 サノフイ Ｃｅａｃａｍ５ ａｄｃ－抗ｐｄ１／ｐｄ－ｌ１組み合わせ療法
WO2023164610A2 (fr) * 2022-02-25 2023-08-31 Atyr Pharma, Inc. Compositions et méthodes comprenant des anticorps anti-nrp2b
AU2023228683B2 (en) 2022-03-02 2025-12-04 Immunitybio, Inc. Method of treating pancreatic cancer
EP4489862A1 (fr) * 2022-03-09 2025-01-15 Merck Patent GmbH Anticorps anti-ceacam5 et conjugués et leurs utilisations
MX2024011519A (es) 2022-03-23 2024-09-24 Synaffix Bv Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario.
US12594323B2 (en) 2022-04-13 2026-04-07 Immunitybio, Inc. Methods of reducing neuroinflammation
WO2024006052A1 (fr) * 2022-06-27 2024-01-04 Agilent Technologies, Inc. Protocoles et méthodes d'immunohistochimie (ihc) permettant le diagnostic et le traitement du cancer
AR130144A1 (es) 2022-08-10 2024-11-06 Merck Sharp & Dohme Llc Proteínas de unión a nkg2d, cd16 y ceacam5
EP4642810A1 (fr) * 2022-12-28 2025-11-05 Full-Life Technologies HK Limited Anticorps se liant spécifiquement au ceacam5
EP4673181A1 (fr) 2023-03-01 2026-01-07 Sanofi Utilisation d'immunoconjugués anti-ceacam5 pour le traitement de cancers neuroendocriniens exprimant ceacam5
EP4427763A1 (fr) 2023-03-06 2024-09-11 Sanofi Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5-médicament, anticorps anti-vegfr-2 et anticorps anti-pd1/pd-l1
CN117545780B (zh) * 2023-05-16 2025-12-30 成都优洛生物科技有限公司 抗lilrb1纳米抗体或其抗原结合片段、制备方法和用途
EP4719483A1 (fr) 2023-06-05 2026-04-08 Sanofi Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5-médicament, des anticorps anti-pd1/pd-l1 et des anticorps anti-ctla4
EP4705354A1 (fr) * 2023-06-05 2026-03-11 Nona Biosciences (Suzhou) Co., Ltd. Anticorps anti-ceacam5
TW202521540A (zh) 2023-08-04 2025-06-01 法商賽諾菲公司 咪唑并[4,5-d]嗒𠯤化合物及其接合物、其製備、及其治療應用
TW202528350A (zh) * 2023-11-10 2025-07-16 大陸商信達生物製藥（蘇州）有限公司 抗ｄｒ５和ｃｅａｃａｍ５的雙特異性抗體及其用途
CN120137043A (zh) * 2023-12-13 2025-06-13 菲鹏生物股份有限公司 抗pivka-ii抗体及其用途
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025169012A1 (fr) 2024-02-06 2025-08-14 Sanofi Méthodes de traitement de cancers exprimant ceacam5
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
US20250361320A1 (en) * 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025242098A1 (fr) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 Conjugué anticorps-médicament ciblant ceacam5 et son utilisation
WO2026002995A1 (fr) 2024-06-24 2026-01-02 Avacta Life Sciences Limited Conjugués inhibiteurs de topoisomérase activés par fap spécifiques à une cible et leurs utilisations
TW202617186A (zh) 2024-06-28 2026-05-01 美商飛爾富來生物公司 Ｂｃｌ－ｘｌ降解劑抗體結合物及其用途
WO2026019161A1 (fr) * 2024-07-19 2026-01-22 주식회사 다안바이오테라퓨틱스 Nouvel anticorps anti-ceacam5 et utilisation associée comme agent thérapeutique
US20260132185A1 (en) 2024-08-19 2026-05-14 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2026043909A1 (fr) 2024-08-19 2026-02-26 HCW Biologics, Inc. Polypeptides chimériques à chaîne unique et leurs utilisations
WO2026052013A1 (fr) * 2024-09-05 2026-03-12 北京泰德制药股份有限公司 Anticorps anti-ceacam5 et son utilisation
WO2026082894A1 (fr) 2024-10-17 2026-04-23 Sanofi Conjugué anticorps-médicament ceacam5 destiné à être utilisé dans le traitement du cancer
WO2026108676A1 (fr) * 2024-11-25 2026-05-28 Wuxi Biologics (Shanghai) Co., Ltd. Anticorps anti-ceacam5, adc et leurs utilisations
WO2026152120A2 (fr) 2025-01-13 2026-07-16 HCW Biologics, Inc. Polypeptides chimériques et utilisations associées

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204A (en) 1847-07-24 james cantelo
US144A (en) 1837-03-11 Improvement in scythe-snaths
US244A (en) 1837-06-30 Edward flint
US4496A (en) 1846-05-02 Machinery for
US4791A (en) 1846-10-03 john g
US4670A (en) 1846-07-28 Improvement in fish-hooks
US417A (en) 1837-09-28 Endless-ghain horse-power for driving iviaci-iii
US689A (en) 1838-04-13 Julius austin
US4640A (en) 1846-07-14 Book-lock
US835A (en) 1838-07-12 X i i i x
US192A (en) 1837-05-15 Machine for cutting
US4301A (en) 1845-12-11 Ebenezbr barrows
US1045773A (en) 1911-08-30 1912-11-26 John A Cole Quick-action electric switch.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (fr) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotique C-15003 PHO et sa préparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1981001145A1 (fr) 1979-10-18 1981-04-30 Univ Illinois Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques
WO1982001188A1 (fr) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd Composes 4,5-deoxymaytansinoide et leur procede de preparation
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
EP0563475B1 (fr) 1992-03-25 2000-05-31 Immunogen Inc Conjugués d'agents ciblés et de dérivés du CC-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
JP3866760B2 (ja) 1993-02-22 2007-01-10 ザ ロックフェラー ユニバーシティ 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2001522241A (ja) 1997-04-10 2001-11-13 ロイヤル ネザーランズ アカデミー オブ アーツ アンド サイエンシズ 診断方法および試薬
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP1542723B1 (fr) 2002-08-16 2011-02-23 ImmunoGen, Inc. Agents de reticulation a reactivite et solubilite elevees et utilisation de ceux-ci dans la preparation de conjugues pour l'administration ciblee de medicaments a petites molecules
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US20050003403A1 (en) 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
WO2007071422A2 (fr) 2005-12-21 2007-06-28 Micromet Ag Compositions d'anticorps pharmaceutique ayant une resistance a cea soluble
NZ569204A (en) 2005-12-21 2012-03-30 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
PT2474557E (pt) 2007-07-16 2014-12-03 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
EP2195023B1 (fr) 2007-08-29 2018-03-07 Sanofi Anticorps anti-cxcr5 humanisés, leurs dérivés et leurs utilisations
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
NZ601815A (en) 2008-03-31 2014-10-31 Genentech Inc Compositions and methods for treating and diagnosing asthma
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
PL3912643T3 (pl) 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
CA2761120A1 (fr) 2009-05-06 2010-11-11 Biotest Ag Utilisations d'immunoconjugues ciblant l'antigene cd138
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
WO2011034660A1 (fr) * 2009-09-16 2011-03-24 Immunomedics, Inc. Anticorps anti-cea de classe i et leurs utilisations
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
KR101981342B1 (ko) * 2011-03-02 2019-05-22 로슈 글리카트 아게 Cea 항체
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
RU2678083C2 (ru) 2012-06-27 2019-01-23 Кенитиро Хасуми Терапия и способ внутриопухолевого введения цитотоксического т-лимфоцита и/или nkt-клетки с антителом против tnf и/или антителом против il-10
PT3199552T (pt) 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
WO2015012904A2 (fr) 2012-12-13 2015-01-29 Immunomedics, Inc. Immunoconjugués anticorps-sn-38 avec un lieur cl2a
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
US9616081B2 (en) 2013-03-27 2017-04-11 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low-dose irinotecan hydrochloride hydrate
EP3066470A4 (fr) 2013-11-05 2017-05-31 Immunomedics, Inc. Anticorps anti-ceacam5 humanisé et ses utilisations
SI3071237T1 (sl) 2013-11-21 2024-11-29 Genmab A/S Liofilizirana formulacija konjugata protitelo-zdravilo
ES2980417T3 (es) 2013-11-25 2024-10-01 Famewave Ltd Composiciones que comprenden anticuerpos anti-CEACAM1 y anti-PD para la terapia del cáncer
EP3145531A4 (fr) 2014-05-02 2018-03-21 Icahn School of Medicine at Mount Sinai Peptides ceacam5 pour la maladie de crohn
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016180941A1 (fr) 2015-05-13 2016-11-17 Sanofi Compositions liquides pour conjugués médicament-anticorps anti-cd19
AU2016274989A1 (en) 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
CN104948958A (zh) * 2015-07-01 2015-09-30 上海顿格电子贸易有限公司 一种利用热敏电阻限流的led灯
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
CN108341876B (zh) * 2017-01-22 2021-06-04 中国人民解放军第四军医大学 抗人ceacam5单克隆抗体及其制备方法和应用
US20200069799A1 (en) 2018-08-28 2020-03-05 Arecor Limited Stabilized antibody protein solutions
KR20210125094A (ko) 2017-04-06 2021-10-15 항저우 디에이씨 바이오테크 씨오, 엘티디 비스-링키지를 사용한 세포독성 약물의 접합
CA3060695A1 (fr) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations stables d'anticorps anti-ctla4 seuls et en combinaison avec des anticorps anti-recepteur de mort programmee 1 (pd-1) et leurs procedes d'utilisation
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018227023A1 (fr) 2017-06-07 2018-12-13 Silverback Therapeutics, Inc. Conjugués de construction d'anticorps
WO2020006486A1 (fr) * 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions et procédés d'administration d'anticorps
WO2020053301A1 (fr) 2018-09-11 2020-03-19 Ichnos Sciences S.A. Compositions comprenant un anticorps bispécifique, un tampon et un ou plusieurs agents stabilisants
SG11202101980VA (en) 2018-09-12 2021-03-30 Silverback Therapeutics Inc Methods and composition for the treatment of disease with immune stimulatory conjugates
WO2020079209A1 (fr) 2018-10-19 2020-04-23 Merck Patent Gmbh Abituzumab pour le traitement du cancer colorectal
KR20210124260A (ko) 2019-02-07 2021-10-14 사노피 폐암을 치료하기 위한 항-ceacam5 면역접합체의 용도
EP3693023A1 (fr) 2019-02-11 2020-08-12 Sanofi Utilisation d'immuno-conjugués anti-ceacam5 pour le traitement du cancer du poumon
EP3937984A1 (fr) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugués ciblant le her2
US20220152215A1 (en) 2019-03-15 2022-05-19 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting CEA
US20220226492A1 (en) 2019-03-15 2022-07-21 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting HER2
WO2020190762A1 (fr) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Agonistes de tlr supportés par des macromolécules
US20220226491A1 (en) 2019-03-15 2022-07-21 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting PD-L1
WO2021067403A1 (fr) 2019-10-01 2021-04-08 Immunomedics, Inc. Biomarqueurs pour une monothérapie ou une polythérapie par un conjugué anticorps-médicament
CA3181000A1 (fr) 2020-04-24 2021-10-28 Sanofi Combinaisons antitumorales contenant des conjugues d'anticorps anti-ceacam5 et du folfiri
BR112022020477A2 (pt) 2020-04-24 2022-11-29 Sanofi Sa Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e cetuximabe
CN115427082A (zh) 2020-04-24 2022-12-02 赛诺菲 含有抗ceacam5抗体缀合物和folfox的抗肿瘤组合
EP4138925A1 (fr) 2020-04-24 2023-03-01 Sanofi Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5, de la trifluridine et du tipiracil
JP7849358B2 (ja) * 2020-11-10 2026-04-21 サノフイ Ｃｅａｃａｍ５抗体－薬物コンジュゲート製剤
AU2022382383A1 (en) 2021-11-05 2024-06-20 Eli Lilly And Company Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
MX2024006766A (es) * 2021-12-02 2024-07-29 Sanofi Sa Prueba de cea para la selección de pacientes en tratamiento del cáncer.
JP2024545427A (ja) 2021-12-02 2024-12-06 サノフイ Ｃｅａｃａｍ５ ａｄｃ－抗ｐｄ１／ｐｄ－ｌ１組み合わせ療法
WO2024108053A1 (fr) * 2022-11-17 2024-05-23 Sanofi Conjugués anticorps-médicaments de ceacam5 et leurs méthodes d'utilisation
EP4673181A1 (fr) 2023-03-01 2026-01-07 Sanofi Utilisation d'immunoconjugués anti-ceacam5 pour le traitement de cancers neuroendocriniens exprimant ceacam5
EP4427763A1 (fr) 2023-03-06 2024-09-11 Sanofi Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5-médicament, anticorps anti-vegfr-2 et anticorps anti-pd1/pd-l1
JP2026511090A (ja) 2023-03-23 2026-04-10 サノフイ 癌治療における患者選択のためのＣＥＡＣＡＭ５ ｍＲＮＡアッセイ
EP4719483A1 (fr) 2023-06-05 2026-04-08 Sanofi Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5-médicament, des anticorps anti-pd1/pd-l1 et des anticorps anti-ctla4
WO2025169012A1 (fr) 2024-02-06 2025-08-14 Sanofi Méthodes de traitement de cancers exprimant ceacam5

Also Published As

Publication number Publication date
EP3199552A1 (fr) 2017-08-02
US20220340682A1 (en) 2022-10-27
UA120247C2 (uk) 2019-11-11
PE20151180A1 (es) 2015-08-12
SI3199552T1 (sl) 2020-06-30
TW201940519A (zh) 2019-10-16
KR102661801B1 (ko) 2024-04-26
CA2889962C (fr) 2023-10-24
RS55987B1 (sr) 2017-09-29
KR20220084193A (ko) 2022-06-21
MY171100A (en) 2019-09-25
EA201590986A1 (ru) 2016-05-31
US20180022817A1 (en) 2018-01-25
CN109180815A (zh) 2019-01-11
HRP20170743T1 (hr) 2017-07-28
AU2013349733B2 (en) 2018-08-23
UY35147A (es) 2014-06-30
HUE033369T2 (en) 2017-11-28
PL3199552T3 (pl) 2020-06-01
AU2013349733A1 (en) 2015-06-11
US20160108131A1 (en) 2016-04-21
PT2922875T (pt) 2017-05-31
PL2922875T3 (pl) 2017-08-31
US9617345B2 (en) 2017-04-11
MX358321B (es) 2018-08-14
DK3199552T3 (da) 2020-03-30
WO2014079886A1 (fr) 2014-05-30
EP3199552B1 (fr) 2019-12-25
AU2018267636A1 (en) 2018-12-13
ECSP15025845A (es) 2016-01-29
CY1119219T1 (el) 2018-02-14
LT3199552T (lt) 2020-04-10
CA3207769A1 (fr) 2014-05-30
CN104918958B (zh) 2019-12-10
IL238559A0 (en) 2015-06-30
US11332542B2 (en) 2022-05-17
CR20150258A (es) 2015-06-11
EP3594243A1 (fr) 2020-01-15
EA039377B1 (ru) 2022-01-20
LT2922875T (lt) 2017-06-12
ZA201502959B (en) 2016-01-27
TWI664192B (zh) 2019-07-01
AU2013349733C1 (en) 2020-10-01
KR20150085828A (ko) 2015-07-24
NZ708528A (en) 2020-07-31
PH12015501092B1 (en) 2019-01-11
CN104918958A (zh) 2015-09-16
DK2922875T3 (en) 2017-06-06
BR112015010993B1 (pt) 2022-08-30
JP2016506370A (ja) 2016-03-03
MA38194B1 (fr) 2018-12-31
KR20200143527A (ko) 2020-12-23
US10457739B2 (en) 2019-10-29
CN109180815B (zh) 2022-06-21
HRP20200415T1 (hr) 2020-06-26
KR102194748B1 (ko) 2020-12-23
KR20240063172A (ko) 2024-05-09
DOP2015000110A (es) 2015-08-16
RS60043B1 (sr) 2020-04-30
ES2778823T3 (es) 2020-08-12
EP2922875B1 (fr) 2017-03-15
JP6324399B2 (ja) 2018-05-16
PT3199552T (pt) 2020-03-25
KR102408660B1 (ko) 2022-06-15
SG11201503285TA (en) 2015-05-28
SI2922875T1 (sl) 2017-06-30
TN2015000177A1 (en) 2016-10-03
CA2889962A1 (fr) 2014-05-30
ES2625742T3 (es) 2017-07-20
IL238559B (en) 2018-10-31
PH12015501092A1 (en) 2015-07-27
BR112015010993A2 (fr) 2017-08-22
AR093557A1 (es) 2015-06-10
CL2015001321A1 (es) 2015-07-17
EP2922875A1 (fr) 2015-09-30
US12570761B2 (en) 2026-03-10
MX2015006374A (es) 2015-10-09
US20200102401A1 (en) 2020-04-02
TW201427997A (zh) 2014-07-16
HK1215444A1 (en) 2016-08-26

Similar Documents

Publication Publication Date Title
MA38194B1 (fr) Anticorps anti-ceacam5 et leurs utilisations
MA45280B1 (fr) Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
PH12023550266A1 (en) Anti-ceacam5 antibodies and conjugates and uses thereof
JOP20220225B1 (ar) ميوتينات إنترليوكين-21 وطرق العلاج
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA52742B1 (fr) Anticorps bispécifiques dll3-cd3
EA202090372A1 (ru) Универсальные соединения авт и их применение
MA40813A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre diverses tumeurs
MA41393A1 (fr) Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers
MA43466A1 (fr) Traitements du cancer de l'utérus
MA49158B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
EA201790986A1 (ru) Антитела к cd73 и их применения
MA46022B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
MA41521A1 (fr) Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers
MA39378B2 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
MA38478A1 (fr) Anticorps anti-pac1 humains
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
MX2021011715A (es) Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención.
MA37407A1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA49155B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation
MA56083B1 (fr) Anticorps humains contre la protéine de pic monoclonal du coronavirus du syndrome respiratoire du moyen-orient
MA37464A1 (fr) Anticorps anti-egfr et leurs utilisations